✨ Free AI Report
Affimed N.V.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Affimed N.V.
Company Research

Affimed N.V.: Business Overview, Financials & Competitive Analysis

Affimed N.V. Research: A Comprehensive Company Overview Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing targeted immunotherapies for cancer patients....

Analyst-debate audio for Affimed N.V.

AskCyborg analysts argue the bull and bear cases for Affimed N.V. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Affimed N.V. Product PortfolioLeadership and Management Team of Affimed N.V.Financial Overview of Affimed N.V.Affimed N.V. Marketing StrategiesAffimed N.V. Market Research and CompetitorsSales Strategies of Affimed N.V.
Get Interactive Report Freeor start reading below
Live on AskCyborg
4/10Mixed
Affimed N.V.

Clinical-stage biotech with differentiated bispecific antibody platform carries high binary risk typical of pre-revenue development-stage companies.

▶︎ Listen to the 90-second analyst debate
Competitors covered:Artiva Biotherapeutics, Inc.
4/ 10Mixed

Cyborg Score thesis

Clinical-stage biotech with differentiated bispecific antibody platform carries high binary risk typical of pre-revenue...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - Immuno-Oncology
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: August 17, 2026
AI-Verified Research
30+ Page Report

Get the Latest Affimed N.V. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Affimed N.V. Research: A Comprehensive Company Overview

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing targeted immunotherapies for cancer patients. Headquartered in Heidelberg, Germany, the company has carved a niche in the biotechnology sector through its innovative approach to cancer treatment. By leveraging the body’s immune system, Affimed aims to provide effective and safe therapies for patients with hematologic and solid tumors.

Affimed N.V. Product Portfolio

Pro stress-test →

Affimed’s product portfolio primarily includes its proprietary bispecific antibody formats, which are designed to harness the power of the innate and adaptive immune systems. The company’s leading product candidates include AFM13, AFM24, and AFM26, which are in various stages of clinical development. These products are targeted at treating different types of cancers, including Hodgkin lymphoma, non-Hodgkin lymphoma, and multiple myeloma.

Leadership and Management Team of Affimed N.V.

Pro stress-test →

Affimed’s leadership team comprises experienced professionals with diverse backgrounds in biotechnology, pharmaceuticals, and business. Key members include Dr. Adi Hoess (CEO), who has extensive experience in the biopharmaceutical industry, and Dr. Wolfgang Fischer (COO), who brings a wealth of knowledge in clinical development and regulatory affairs. The management team is complemented by a robust board of directors and advisory board, ensuring strategic guidance and oversight.

Financial Overview of Affimed N.V.

Pro stress-test →

Affimed N.V. has demonstrated a strong financial performance, with significant investments in research and development. The company has successfully raised funds through public offerings and collaborations, ensuring a steady flow of capital to support its clinical programs. Key financial metrics, such as revenue, net income, and R&D expenditure, reflect the company’s commitment to advancing its pipeline and achieving long-term growth.

Affimed N.V. Marketing Strategies

Affimed employs a multi-faceted marketing approach to raise awareness about its innovative therapies. This includes engaging with the medical community through conferences, scientific publications, and collaborations with key opinion leaders. The company also leverages digital marketing channels to reach a broader audience, ensuring that stakeholders are well-informed about its developments and achievements.

Affimed N.V. Market Research and Competitors

The biotechnology market is highly competitive, with numerous companies vying for leadership in the immunotherapy space. Affimed N.V. faces competition from both large pharmaceutical companies and smaller biotech firms. Key competitors include Genmab, MacroGenics, and Xencor, among others. Despite the competition, Affimed’s unique approach and promising clinical data position it favorably in the market.

Sales Strategies of Affimed N.V.

Affimed’s sales strategy focuses on strategic partnerships and collaborations to advance its clinical programs and commercialize its products. The company has entered into agreements with leading pharmaceutical companies, such as Roche and Merck, to leverage their expertise and resources. These partnerships enhance Affimed’s ability to bring its therapies to market and reach patients globally.

Technologies Utilized by Affimed N.V.

Affimed’s technological prowess lies in its proprietary Redirected Optimized Cell Killing (ROCK®) platform, which is designed to generate highly specific and potent immune cell engagers. This technology enables the development of bispecific antibodies that can simultaneously target cancer cells and activate immune cells, leading to enhanced anti-tumor activity. The ROCK® platform is a cornerstone of Affimed’s research and development efforts.

HR Practices at Affimed N.V.

Affimed places a strong emphasis on its human resources practices, fostering a culture of innovation, collaboration, and professional growth. The company offers competitive compensation packages, comprehensive benefits, and opportunities for career advancement. Affimed also prioritizes diversity and inclusion, ensuring a supportive work environment for employees from various backgrounds.

Corporate Social Responsibility Initiatives

Affimed is committed to corporate social responsibility, actively participating in initiatives that benefit society and the environment. The company supports various charitable organizations, engages in community outreach programs, and implements sustainable practices within its operations. Affimed’s dedication to social responsibility reflects its broader mission to improve patient outcomes and contribute positively to the world.

Future Plans and Strategies of Affimed N.V.

Looking ahead, Affimed N.V. aims to continue advancing its clinical pipeline and expanding its portfolio of innovative therapies. The company plans to initiate new clinical trials, pursue regulatory approvals, and explore additional indications for its product candidates. By maintaining a focus on scientific excellence and strategic partnerships, Affimed is well-positioned to achieve its vision of transforming cancer treatment.

For a more detailed analysis and comprehensive insights into Affimed N.V., including in-depth financial data, competitive landscape, and strategic initiatives, consider purchasing the full report from AskCyborg.com.


Get your detailed report on Affimed N.V. by subscribing to our service

What the analysts stress-tested

The top findings that survived the multi-agent debate for Affimed N.V..

+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Affimed N.V. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

AlloNKAllogeneic NK cell therapy combined with AFM13 in clinical developmentPD-L1 inhibitorsAtezolizumab checkpoint inhibitor combined with AFM24 in Phase IIa studiesNK cell therapiesCompeting NK cell engagement and adoptive cell therapy approaches

Compare Affimed N.V. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Affimed N.V. operates in Biopharmaceuticals - Immuno-Oncology. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - Immuno-Oncology research →
NEW · MCP server

Ask your AI assistant about Affimed N.V.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Affimed N.V. and its top competitor on Cyborg Score”
“What did Affimed N.V. do this quarter?”
“Is Affimed N.V. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Affimed N.V. do?+
Affimed N.V. Research: A Comprehensive Company Overview Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing targeted immunotherapies for cancer patients....
What is Affimed N.V.'s Cyborg Score?+
Affimed N.V. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Affimed N.V.'s main competitors?+
Named competitors include AlloNK, PD-L1 inhibitors, NK cell therapies. The full competitive landscape is in the AskCyborg report.
How can I get the full Affimed N.V. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Affimed N.V. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Affimed N.V. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Company Research

Ai Infrastructure Systems Industry BriefingPet Insurance Industry BriefingSelf-Storage Industry BriefingMetal Additive Manufacturing Industry BriefingAi Accelerator Hardware Systems Industry BriefingLuxury Wines & Spirits Industry BriefingEnzymatic Plastic Recycling Industry BriefingInfrastructure as a Service (IaaS) Industry Briefingluxury fashion apparel Industry BriefingPremium Consumer Smartphones And Integrated Ecosystem Services Industry BriefingMulti Cloud Management Industry BriefingCloud Based Omnichannel Fulfillment And Logistics Industry Briefing

Explore Industry Research

Travel Insurance Industry Company Research ReportSecurity Services Industry Company Research ReportLandscaping and Grounds Maintenance Industry Company Research ReportJanitorial and Cleaning Services Industry Company Research ReportSustainability Consulting Industry Company Research ReportReal Estate Investment Trusts (REITs) Industry Company Research Report
Browse All Company ResearchBrowse All Industry ResearchRSS Feed